- Home
- RPRX vs XPEV Comparison
RPRX vs XPEV Comparison
Compare RPRX & XPEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | XPEV |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 20.2B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RPRX | XPEV |
|---|---|---|
| Price | $39.70 | $20.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $46.00 | $24.90 |
| AVG Volume (30 Days) | 4.3M | ★ 18.2M |
| Earning Date | 11-05-2025 | 11-17-2025 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | $2,349,844,000.00 | ★ $9,912,782,208.00 |
| Revenue This Year | $37.13 | $99.25 |
| Revenue Next Year | $1.48 | $39.50 |
| P/E Ratio | $22.68 | ★ N/A |
| Revenue Growth | 3.70 | ★ 86.64 |
| 52 Week Low | $24.05 | $11.14 |
| 52 Week High | $41.24 | $28.24 |
Technical Indicators
Market Signals| Indicator | RPRX | XPEV |
|---|---|---|
| Relative Strength Index (RSI) | 57.50 | 42.33 |
| Support Level | $39.24 | $18.55 |
| Resistance Level | $40.50 | $21.99 |
| Average True Range (ATR) | 0.91 | 0.87 |
| MACD | -0.08 | -0.33 |
| Stochastic Oscillator | 76.02 | 26.04 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About XPEV XPeng Inc.
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 190,000 EVs in 2024, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.